Back

Superior actions of chronic peptide therapeutics with Cenderitide on cardiorenal function and remodeling compared to enalapril through reverse activation of gene pathways in experimental heart failure

27 August 2016 (11:50 - 12:00)
Organised by:
Congress Presentation Part of: Drug therapy of heart failure Pharmacologic therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Tomoko Ichiki

Mayo Clinic, Rochester (United States of America)

8 More presentations in this session

Presentation thumbnail
Are beta-blockers needed in patients after primary prevention implantable cardioverter-defibrillator? A multicenter population-based cohort study.
Professor L. Fauchier (Tours, FR)
Abstract Slides Video
Presentation thumbnail
Non-withdrawal of beta-blockers in acute decompensated chronic and de-novo heart failure is associated with lower in-hospital and 3-months mortality: Findings from the GULF-CARE
Assistant Professor C. Abi Khalil (Doha, QA)
Abstract
Presentation thumbnail
Beta-blockers, ACE/ARB and MRA at discharge and outcome after hospitalization of heart failure in octogenarians with HFPEF and HFREF: a report from the BIO-HF registry
Professor J. De Sutter (Gent, BE)
Abstract Slides Video
Presentation thumbnail
Fingerprint of the renin-angiotensin-system during ARNI therapy in patients with systolic heart failure
Doctor R. Wurm (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Anti hypertrophic effects of LCZ696 in chronic cardiac pressure overload
Mr E. Sjaastad Norden (Oslo, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy of heart failure

The Event

Event poster

ESC Congress 2016

27 August 2016 11:50 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources